Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | PLTP | P55058 | 4/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317084 | 0.90 | MAPT (0.45) | RORCMAPTPLTPNTRK1LMNA | |
| SCHEMBL2318318 | 0.89 | FPR2 (0.46) | RORCMAPTPTGDR2PLTPFPR2 | |
| SCHEMBL2484995 | 0.89 | PLTP (0.51) | RORCDHODHPTGDR2PLTPDGAT1 | |
| SCHEMBL2317569 | 0.87 | AR (0.52) | RORCMAPTDHODHPLTPLMNA | |
| SCHEMBL2315078 | 0.86 | DHODH (0.49) | RORCMAPTDHODHPLTP | |
| SCHEMBL2312534 | 0.85 | RORC (0.54) | RORCDHODHPTGDR2PLTPDGAT1 | |
| SCHEMBL2316628 | 0.82 | RORC (0.48) | RORCMAPTPLTPHTTDGAT1 | |
| SCHEMBL2360023 | 0.82 | TRPV1 (0.49) | RORCMAPTDHODHPLTPLMNA | |
| SCHEMBL2312708 | 0.81 | TP53 (0.50) | RORCMAPTPTGDR2PLTPDGAT1 | |
| SCHEMBL2485677 | 0.81 | PLTP (0.51) | RORCMAPTPTGDR2PLTPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2380631-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2349484-A2 | HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS | Novartis AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| WO-2010007046-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022513-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | RORC 1166/4885MAPT 1671/4885DHODH 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.